New Drugs for HDL-C Disorders: The Beginning

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|21|25|2947-2951

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.25, 2014-08, pp. : 2947-2951

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lean Times Looming in the Lipid-Lowering Market: Statin Slump Certain But Hope for HDL-C Drugs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 11, 2006-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels

By  

Current Drug Targets, Vol. 8, Iss. 3, 2007-01 ,pp. : 483-488

Bentham Science Publishers

Access to resources Recommend Favorite

HDL-C predictive of CV events in statin users

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality

By  

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3841-3857

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C

By Teramoto Tamio  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 859-865

Informa Healthcare

Access to resources Recommend Favorite